Characterization of High-Risk-Other Human Papillomavirus Genotypes in Papanicolaou Tests, High-Grade Squamous Intraepithelial Lesions, and Cervical Cancer.

IF 1.3 Q2 MEDICINE, GENERAL & INTERNAL
Caitlin E Witt, Elizabeth F Sutton, Ashley M Stansbury, Ashley N Winters, Luke C Konur, Meng Luo, Jennifer E Cameron, Beverly Ogden
{"title":"Characterization of High-Risk-Other Human Papillomavirus Genotypes in Papanicolaou Tests, High-Grade Squamous Intraepithelial Lesions, and Cervical Cancer.","authors":"Caitlin E Witt, Elizabeth F Sutton, Ashley M Stansbury, Ashley N Winters, Luke C Konur, Meng Luo, Jennifer E Cameron, Beverly Ogden","doi":"10.31486/toj.24.0018","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> The objective of this study was to determine the human papillomavirus (HPV) genotypes of high-risk-other HPV Papanicolaou (Pap) tests and of biopsy tissues from patients with high-grade squamous intraepithelial lesion (HGSIL) or cervical cancer. High-risk-other HPV status was determined with the cobas HPV Test (Roche Diagnostics, North America) that identifies 12 high-risk, non-16/18 HPV genotypes. We hypothesized that we would find genotypes of HPV in our population that are not covered by the 9-valent HPV vaccine. <b>Methods:</b> For this retrospective cohort study, we randomly selected 50 high-risk-other HPV Pap test samples from 2018 from our pathology department registries for HPV genotype determination by Roche Linear Array (Roche Diagnostics, North America). Then we randomly selected 76 cervical biopsy samples of HGSIL or cervical cancer with high-risk-other HPV or HPV unknown status from 2016 to 2022 for HPV genotype determination by next-generation sequencing. Results are reported as counts and frequencies. <b>Results:</b> In the 50 high-risk-other HPV Pap test samples, 21 genotypes of HPV were noted; the most common were 53 (n=6), 51 (n=6), and 59 (n=5). In the samples with HGSIL or cervical cancer, 16 HPV genotypes were detected; the most common were 16 (n=26), 58 (n=12), and 33 (n=8). Among the patients with HGSIL or cervical cancer, the 9-valent HPV vaccine provided coverage for all the HPV variants found in 88% of patients, partial coverage in 8% of patients, and no coverage in 4% of patients. <b>Conclusion:</b> The 3 most common HPV genotypes seen in our high-risk-other HPV Pap test samples are not covered by the 9-valent HPV vaccine. For the HGSIL and cancer samples, 88% of the samples had full HPV genotype coverage with the 9-valent HPV vaccine. This study highlights a presence of HPV that will not be protected by vaccination in a high-risk population.</p>","PeriodicalId":47600,"journal":{"name":"Ochsner Journal","volume":"24 3","pages":"179-183"},"PeriodicalIF":1.3000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11398616/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ochsner Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31486/toj.24.0018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The objective of this study was to determine the human papillomavirus (HPV) genotypes of high-risk-other HPV Papanicolaou (Pap) tests and of biopsy tissues from patients with high-grade squamous intraepithelial lesion (HGSIL) or cervical cancer. High-risk-other HPV status was determined with the cobas HPV Test (Roche Diagnostics, North America) that identifies 12 high-risk, non-16/18 HPV genotypes. We hypothesized that we would find genotypes of HPV in our population that are not covered by the 9-valent HPV vaccine. Methods: For this retrospective cohort study, we randomly selected 50 high-risk-other HPV Pap test samples from 2018 from our pathology department registries for HPV genotype determination by Roche Linear Array (Roche Diagnostics, North America). Then we randomly selected 76 cervical biopsy samples of HGSIL or cervical cancer with high-risk-other HPV or HPV unknown status from 2016 to 2022 for HPV genotype determination by next-generation sequencing. Results are reported as counts and frequencies. Results: In the 50 high-risk-other HPV Pap test samples, 21 genotypes of HPV were noted; the most common were 53 (n=6), 51 (n=6), and 59 (n=5). In the samples with HGSIL or cervical cancer, 16 HPV genotypes were detected; the most common were 16 (n=26), 58 (n=12), and 33 (n=8). Among the patients with HGSIL or cervical cancer, the 9-valent HPV vaccine provided coverage for all the HPV variants found in 88% of patients, partial coverage in 8% of patients, and no coverage in 4% of patients. Conclusion: The 3 most common HPV genotypes seen in our high-risk-other HPV Pap test samples are not covered by the 9-valent HPV vaccine. For the HGSIL and cancer samples, 88% of the samples had full HPV genotype coverage with the 9-valent HPV vaccine. This study highlights a presence of HPV that will not be protected by vaccination in a high-risk population.

宫颈巴氏涂片检验、高级别鳞状上皮内病变和宫颈癌中的高危-其他人类乳头瘤病毒基因型的特征。
研究背景本研究旨在确定宫颈巴氏涂片(Pap)检查和高级别鳞状上皮内病变(HGSIL)或宫颈癌患者活检组织中的高危其他 HPV(HPV)基因型。高危其他 HPV 状态是通过 cobas HPV 检测仪(罗氏诊断公司,北美)确定的,该检测仪可识别 12 种高危非 16/18 型 HPV 基因型。我们假设在我们的人群中会发现 9 价 HPV 疫苗未覆盖的 HPV 基因型。方法:在这项回顾性队列研究中,我们从病理科登记处随机抽取了 50 份 2018 年的高危其他 HPV Pap 测试样本,通过罗氏线性阵列(罗氏诊断,北美)进行 HPV 基因型测定。然后,我们从2016年至2022年随机选取了76份HGSIL或宫颈癌的宫颈活检样本,这些样本带有高危-其他HPV或HPV未知状态,通过新一代测序进行HPV基因型测定。结果以计数和频率形式报告。结果在50份高危-其他HPV巴氏试验样本中,发现了21种HPV基因型;最常见的是53(n=6)、51(n=6)和59(n=5)。在 HGSIL 或宫颈癌样本中,检测到 16 种 HPV 基因型;最常见的是 16(n=26)、58(n=12)和 33(n=8)。在 HGSIL 或宫颈癌患者中,9 价 HPV 疫苗覆盖了 88% 的患者所发现的所有 HPV 变体,部分覆盖了 8% 的患者,4% 的患者没有覆盖。结论9价HPV疫苗不能覆盖我们的高危HPV巴氏试验样本中最常见的3种HPV基因型。在 HGSIL 和癌症样本中,88% 的样本在接种 9 价 HPV 疫苗后实现了完全的 HPV 基因型覆盖。这项研究强调了在高危人群中存在疫苗接种无法保护的 HPV。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Ochsner Journal
Ochsner Journal MEDICINE, GENERAL & INTERNAL-
CiteScore
2.10
自引率
0.00%
发文量
71
审稿时长
24 weeks
期刊介绍: The Ochsner Journal is a quarterly publication designed to support Ochsner"s mission to improve the health of our community through a commitment to innovation in healthcare, medical research, and education. The Ochsner Journal provides an active dialogue on practice standards in today"s changing healthcare environment. Emphasis will be given to topics of great societal and medical significance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信